ACT Capital Partners, L.P.’s Kazia Therapeutics KZIA Stock Holding History

ACT Capital Partners, L.P.’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$336K	Buy	+35,000	New	+$439K	0.22%	42

Other funds holding KZIA

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return

Westside Investment Management Santa Monica, California $785M AUM 29.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

T3 Companies New York $103M AUM 54.73% 1-Year Est. Return

ORG Wealth Partners Dallas, Texas $607M AUM 23.88% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

ACT Capital Partners, L.P.'s KZIA Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Kazia Therapeutics (KZIA) in Q3 2026: 35,000 shares worth $336K. The stake represents 0.22% of the portfolio and ranks #42 among its holdings.

11 funds tracked by Wall St. Rank hold KZIA as of Q3 2026.

ACT Capital Partners, L.P. held 35,000 shares of Kazia Therapeutics worth $336K as of Q3 2026.
Kazia Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
Kazia Therapeutics made up 0.22% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #42 holding.
11 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.